CL2018002705A1 - Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales - Google Patents

Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales

Info

Publication number
CL2018002705A1
CL2018002705A1 CL2018002705A CL2018002705A CL2018002705A1 CL 2018002705 A1 CL2018002705 A1 CL 2018002705A1 CL 2018002705 A CL2018002705 A CL 2018002705A CL 2018002705 A CL2018002705 A CL 2018002705A CL 2018002705 A1 CL2018002705 A1 CL 2018002705A1
Authority
CL
Chile
Prior art keywords
lactone
treatment
fungal infections
glucono delta
vaginal fungal
Prior art date
Application number
CL2018002705A
Other languages
English (en)
Inventor
Ulf Ellervik
Olov Sterner
Helena Strevens
Sophie Manner
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of CL2018002705A1 publication Critical patent/CL2018002705A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B14/10—Crucibles
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B3/00—Hearth-type furnaces, e.g. of reverberatory type; Tank furnaces
    • F27B3/10—Details, accessories, or equipment peculiar to hearth-type furnaces
    • F27B3/12—Working chambers or casings; Supports therefor
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D1/00—Casings; Linings; Walls; Roofs
    • F27D1/16—Making or repairing linings increasing the durability of linings or breaking away linings
    • F27D1/1626—Making linings by compacting a refractory mass in the space defined by a backing mould or pattern and the furnace wall
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/22—Furnaces without an endless core
    • H05B6/24—Crucible furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F27B2014/066—Construction of the induction furnace
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B2014/0837—Cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN VAGINAL, QUE COMPRENDE UN EXCIPIENTE FARMACÉUTICAMENTE ACEPTABLE Y GLUCONO D-LACTONA, DONDE LA GLUCONO D-LACTONA ESTÁ PRESENTE EN UNA CANTIDAD DE 5 A 99% EN PESO DE LA FORMULACIÓN. LA INVENCIÓN TAMBIÉN SE REFIERE AL USO DE LA FORMULACIÓN EN LA PREVENCIÓN O TRATAMIENTO DE UNA INFECCIÓN FÚNGICA UROGENITAL, Y AL USO DE LA GLUCONO D-LACTONA (FÓRMULA (III)) EN LA PREVENCIÓN O TRATAMIENTO DE UNA INFECCIÓN FÚNGICA.
CL2018002705A 2016-04-06 2018-09-25 Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales CL2018002705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650467 2016-04-06

Publications (1)

Publication Number Publication Date
CL2018002705A1 true CL2018002705A1 (es) 2018-11-30

Family

ID=58530540

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002705A CL2018002705A1 (es) 2016-04-06 2018-09-25 Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales

Country Status (22)

Country Link
US (2) US10993907B2 (es)
EP (1) EP3439633B1 (es)
JP (1) JP6967785B2 (es)
KR (1) KR102346658B1 (es)
CN (1) CN109069413B (es)
AU (1) AU2017248050B2 (es)
BR (1) BR112018070370A2 (es)
CA (1) CA3013809C (es)
CL (1) CL2018002705A1 (es)
DK (1) DK3439633T3 (es)
EA (1) EA036748B1 (es)
ES (1) ES2896680T3 (es)
HU (1) HUE056303T2 (es)
IL (1) IL261796B (es)
MX (1) MX2018012210A (es)
MY (1) MY198473A (es)
PH (1) PH12018502131A1 (es)
PL (1) PL3439633T3 (es)
SG (1) SG11201807475VA (es)
UA (1) UA123954C2 (es)
WO (1) WO2017174731A1 (es)
ZA (1) ZA201804938B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11612584B2 (en) 2017-10-06 2023-03-28 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
BR112021019999A2 (pt) 2019-04-05 2021-12-07 Gedea Biotech Ab Formulação de comprimido vaginal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234599A (en) 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5942250A (en) * 1986-12-23 1999-08-24 Tristrata Technology, Inc. Compositions and methods for enhancing the topical effects of sunscreen agents
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CN1051454C (zh) 1994-12-13 2000-04-19 周彦华 含有葡萄糖酸δ-内酯的阴道避孕药
WO1999066904A1 (en) 1998-06-25 1999-12-29 Theratech, Inc. INCORPORATION OF LATENT ACID SOLUBILIZING AGENTS IN COATED PELLET FORMULATIONS TO OBTAIN pH INDEPENDENT RELEASE
AT407111B (de) * 1998-12-22 2000-12-27 Gergely Dr & Co Zucker- und/oder zuckeralkoholhältiges matrixmaterial und verfahren zu seiner herstellung
AUPP839499A0 (en) 1999-01-29 1999-02-25 Australian National University, The A method for controlling plant pathogens, and agents useful for same
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
NZ575241A (en) 2002-08-12 2010-10-29 Lonza Ag Antimicrobial compositions
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US20070059278A1 (en) 2005-09-12 2007-03-15 Nawaz Ahmad Anhydrous composition containing an acid-acid buffer system
EP2099504A1 (en) 2006-12-15 2009-09-16 Ellen Aktiebolag Absorbent article comprising lactic acid producing bacteria
WO2008119518A1 (en) 2007-03-30 2008-10-09 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological disorders
CN101808638B (zh) 2007-09-05 2012-07-25 宝丽制药股份有限公司 抗真菌组合物
US20170173056A1 (en) 2014-03-20 2017-06-22 Cheryl Lee Eberting Compositions for the treatment of dermatological diseases and disorders

Also Published As

Publication number Publication date
PL3439633T3 (pl) 2022-01-10
MX2018012210A (es) 2018-12-17
MY198473A (en) 2023-08-31
CA3013809A1 (en) 2017-10-12
KR102346658B1 (ko) 2022-01-03
WO2017174731A1 (en) 2017-10-12
AU2017248050B2 (en) 2022-05-26
IL261796B (en) 2021-06-30
EP3439633A1 (en) 2019-02-13
EA201891744A1 (ru) 2019-03-29
PH12018502131A1 (en) 2019-09-16
AU2017248050A1 (en) 2018-11-08
US10993907B2 (en) 2021-05-04
US20210212937A1 (en) 2021-07-15
KR20180127314A (ko) 2018-11-28
HUE056303T2 (hu) 2022-02-28
UA123954C2 (uk) 2021-06-30
JP2019510761A (ja) 2019-04-18
CN109069413B (zh) 2022-09-27
EA036748B1 (ru) 2020-12-16
IL261796A (en) 2018-10-31
SG11201807475VA (en) 2018-10-30
CA3013809C (en) 2024-01-02
US20190110983A1 (en) 2019-04-18
CN109069413A (zh) 2018-12-21
US11696891B2 (en) 2023-07-11
ZA201804938B (en) 2022-03-30
ES2896680T3 (es) 2022-02-25
BR112018070370A2 (pt) 2019-01-29
EP3439633B1 (en) 2021-09-15
JP6967785B2 (ja) 2021-11-17
DK3439633T3 (da) 2021-12-20

Similar Documents

Publication Publication Date Title
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112015007742B8 (pt) composto, composição farmacêutica, e, uso do referido composto
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
PE20200336A1 (es) Formulaciones a largo plazo
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine